Skip to content

Anika Therapeutics ANIK Ratios & Valuation

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Net margin-9.8%+0.1pp-9.9%+30.3pp-40.2%+24.9pp-65.1%-12.0pp-53.1%-6.6pp
Returns
Return on equity-8%-0.5pp-7.5%+12.7pp-20.2%+13.6pp-33.9%-2.1pp-31.8%-1.0pp
Efficiency
Asset turnover0.6×+0.1×0.6×+0.2×0.4×0.0×0.4×-0.1×0.5×0.0×
Liquidity
Current ratio4.5×-0.3×4.7×-0.6×5.3×-0.9×6.2×+0.4×5.7×+0.8×
Leverage
Debt-to-equity0.2×0.0×0.2×0.0×0.2×0.0×0.2×0.0×0.2×0.0×
Valuation
Market capitalization$204.37M+31.6%$138.59M+2.3%$135.53M-15.8%$161.05M-24.4%$213.07M-11.6%
Price / sales1.8×+0.1×1.2×-0.4×1.6×-0.1×1.7×-0.3×0.0×
Price / book1.5×+0.5×0.0×0.9×-0.2×1.1×-0.3×1.4×-0.1×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Anika Therapeutics's ratios come from?
Every ratio is computed from Anika Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.